Title:
HETEROCYCLIC COMPOUND
Document Type and Number:
WIPO Patent Application WO/2021/020585
Kind Code:
A1
Abstract:
To provide a novel heterocyclic compound which has an effect of inducing the degradation of IRAK-M protein and which is expected to be useful for preventing or treating cancer, fibrosis, infectious diseases, etc., and a medicine comprising the same. The invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Inventors:
TOMINARI YUSUKE (JP)
TOMATA YOSHIHIDE (JP)
GAMO KANAE (JP)
KITAMOTO NAOMI (JP)
TOMATA YOSHIHIDE (JP)
GAMO KANAE (JP)
KITAMOTO NAOMI (JP)
Application Number:
PCT/JP2020/029589
Publication Date:
February 04, 2021
Filing Date:
July 31, 2020
Export Citation:
Assignee:
FIMECS INC (JP)
International Classes:
C07D495/04; A61K31/4365; A61K31/496; A61K45/00; A61P35/00; A61P43/00; C07K5/083
Domestic Patent References:
| WO2017211924A1 | 2017-12-14 | |||
| WO2019099926A1 | 2019-05-23 | |||
| WO2019133531A1 | 2019-07-04 | |||
| WO2018066545A1 | 2018-04-12 | |||
| WO2016169989A1 | 2016-10-27 | |||
| WO2016172134A2 | 2016-10-27 | |||
| WO2017011590A1 | 2017-01-19 | |||
| WO2017182418A1 | 2017-10-26 | |||
| WO2017201449A1 | 2017-11-23 | |||
| WO2018119448A1 | 2018-06-28 | |||
| WO2018119357A1 | 2018-06-28 | |||
| WO2006113376A1 | 2006-10-26 | |||
| WO2007104162A1 | 2007-09-20 | |||
| WO2007106192A2 | 2007-09-20 | |||
| WO2007131366A1 | 2007-11-22 | |||
| WO2008016893A1 | 2008-02-07 | |||
| WO2008045905A1 | 2008-04-17 | |||
| WO2008079735A1 | 2008-07-03 | |||
| WO2008128171A2 | 2008-10-23 | |||
| WO2010142994A1 | 2010-12-16 | |||
| WO2011002684A1 | 2011-01-06 | |||
| WO2011098904A1 | 2011-08-18 | |||
| WO2012143726A1 | 2012-10-26 | |||
| WO2014023708A1 | 2014-02-13 | |||
| WO2014060770A1 | 2014-04-24 | |||
| WO2016040330A1 | 2016-03-17 | |||
| WO2013019966A1 | 2013-02-07 | |||
| WO2011005761A1 | 2011-01-13 |
Foreign References:
| JP2019517559A | 2019-06-24 | |||
| JP2013056837A | 2013-03-28 | |||
| US20180118733A1 | 2018-05-03 | |||
| US20180134688A1 | 2018-05-17 | |||
| US20190119271A1 | 2019-04-25 | |||
| US20190175612A1 | 2019-06-13 | |||
| US20070093428A1 | 2007-04-26 | |||
| JP2012106958A | 2012-06-07 | |||
| JP2012176934A | 2012-09-13 | |||
| US20130172264A1 | 2013-07-04 | |||
| US20140135270A1 | 2014-05-15 | |||
| US20130040957A1 | 2013-02-14 | |||
| CN103242341A | 2013-08-14 |
Other References:
ANONYMOUS: "Targeted IRAK-M degradation as a novel and efficacious cancer-immunotherapy overcoming innate-driven immunosuppression", AACR ANNUAL MEETING 2019, 28 February 2019 (2019-02-28), pages 1 - 2, XP055901761
TOMINARI YUSUKE: "Phymex's target proteolysis induction technology", FARUMASHIA, vol. 56, no. 3, 1 March 2020 (2020-03-01), pages 248 - 250, XP055789303
GAMO,K. ET AL.: "Targeted IRAK -M degradation as a novel and efficacious cancer-immunotherapy overcoming innate-driven immunosuppression", IMMUNOLOGY, MOLECULAR MECHANISMS IN THE IMMUNE RESPONSE TO CANCER, vol. 24, no. 8, 1 April 2019 (2019-04-01), Georgia World Congress Center, pages 2354, XP055789308, Retrieved from the Internet
SCIENCE, vol. 355, no. 6330, 17 March 2017 (2017-03-17), pages 1163 - 1167
CELL CHEM BIOL., vol. 25, no. l, 18 January 2018 (2018-01-18), pages 78 - 87
CELL CHEM. BIOL., vol. 24, no. 9, 21 September 2017 (2017-09-21), pages 1181 - 1190
ACS CHEM BIOL., vol. 12, no. 4, 21 April 2017 (2017-04-21), pages 892 - 898
NAT REV DRUG DISCOV, vol. 16, no. 2, February 2017 (2017-02-01), pages 101 - 114
NAT CHEM BIOL., vol. 11, no. 8, August 2015 (2015-08-01), pages 611 - 7
CHEMISTRY & BIOLOGY, vol. 17, no. 6, 2010, pages 551 - 555
CHEMBIOCHEM, vol. 6, no. 1, 2005, pages 40 - 46
J BIOL CHEM, vol. 274, no. 27, 2 July 1999 (1999-07-02), pages 19403 - 19410
CELL, vol. 110, no. 2, 26 July 2002 (2002-07-26), pages 191 - 202
INFECT DIS REP, vol. 2, no. 1, 1 January 2010 (2010-01-01), pages e9
ONCOGENE, vol. 30, no. 21, 26 May 2011 (2011-05-26), pages 2475 - 2484
J IMMUNOL, vol. 185, no. 7, 1 October 2010 (2010-10-01), pages 4223 - 4232
MOL IMMUNOL, vol. 44, no. 14, July 2007 (2007-07-01), pages 3453 - 3461
J IMMUNOL, vol. 194, no. 4, 15 February 2015 (2015-02-15), pages 1894 - 1904
J CLIN INVEST, vol. 116, no. 9, 17 August 2006 (2006-08-17), pages 2532 - 2542
J IMMUNOL, vol. 184, no. 11, 1 June 2010 (2010-06-01), pages 6299 - 6308
STRATEGIC APPLICATIONS OF NAMED REACTIONS IN ORGANIC SYNTHESIS, vol. I-VII
"Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
J. F. HARTWIGS. SHEKHARQ. SHENF. BARRIOS-LANDEROS: "Protective Groups in Organic Synthesis", 2007, WILEY-INTERSICENCE
L. JIANGS. L. BUCHWALD: "Metal-Catalyzed Cross-Coupling Reactions", 2004, WILEY-VCH
J. F. HARTWIG: "Handbook of Organopalladium Chemistry for Organic Synthesis", 2002, WILEY
J. F. HARTWIG: "Modern Amination Methods", 2000, WILEY-VCH
IYAKUHINKAIHATSU: "Development of Pharmaceuticals", vol. 7, 1990, HIROKAWA SHOTEN, article "Design of Molecules", pages: 163 - 198
CHEM. REV., vol. 114, 2014, pages 9154 - 9218
PHARMA. RES., vol. 32, 2015, pages 3526 - 3540
BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
THE AAPS JOURNAL, vol. 17, 2015, pages 339 - 351
GOLDSTEIN, D. M. ET AL.: "High-throughput kinase profiling as a platform for drug discovery", NAT. REV. DRUG DISCOVERY, vol. 7, 2008, pages 391 - 397, XP002544968, DOI: 10.1038/nrd2541
See also references of EP 4006037A4
TOMINARI YUSUKE: "Phymex's target proteolysis induction technology", FARUMASHIA, vol. 56, no. 3, 1 March 2020 (2020-03-01), pages 248 - 250, XP055789303
GAMO,K. ET AL.: "Targeted IRAK -M degradation as a novel and efficacious cancer-immunotherapy overcoming innate-driven immunosuppression", IMMUNOLOGY, MOLECULAR MECHANISMS IN THE IMMUNE RESPONSE TO CANCER, vol. 24, no. 8, 1 April 2019 (2019-04-01), Georgia World Congress Center, pages 2354, XP055789308, Retrieved from the Internet
SCIENCE, vol. 355, no. 6330, 17 March 2017 (2017-03-17), pages 1163 - 1167
CELL CHEM BIOL., vol. 25, no. l, 18 January 2018 (2018-01-18), pages 78 - 87
CELL CHEM. BIOL., vol. 24, no. 9, 21 September 2017 (2017-09-21), pages 1181 - 1190
ACS CHEM BIOL., vol. 12, no. 4, 21 April 2017 (2017-04-21), pages 892 - 898
NAT REV DRUG DISCOV, vol. 16, no. 2, February 2017 (2017-02-01), pages 101 - 114
NAT CHEM BIOL., vol. 11, no. 8, August 2015 (2015-08-01), pages 611 - 7
CHEMISTRY & BIOLOGY, vol. 17, no. 6, 2010, pages 551 - 555
CHEMBIOCHEM, vol. 6, no. 1, 2005, pages 40 - 46
J BIOL CHEM, vol. 274, no. 27, 2 July 1999 (1999-07-02), pages 19403 - 19410
CELL, vol. 110, no. 2, 26 July 2002 (2002-07-26), pages 191 - 202
INFECT DIS REP, vol. 2, no. 1, 1 January 2010 (2010-01-01), pages e9
ONCOGENE, vol. 30, no. 21, 26 May 2011 (2011-05-26), pages 2475 - 2484
J IMMUNOL, vol. 185, no. 7, 1 October 2010 (2010-10-01), pages 4223 - 4232
MOL IMMUNOL, vol. 44, no. 14, July 2007 (2007-07-01), pages 3453 - 3461
J IMMUNOL, vol. 194, no. 4, 15 February 2015 (2015-02-15), pages 1894 - 1904
J CLIN INVEST, vol. 116, no. 9, 17 August 2006 (2006-08-17), pages 2532 - 2542
J IMMUNOL, vol. 184, no. 11, 1 June 2010 (2010-06-01), pages 6299 - 6308
STRATEGIC APPLICATIONS OF NAMED REACTIONS IN ORGANIC SYNTHESIS, vol. I-VII
"Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
J. F. HARTWIGS. SHEKHARQ. SHENF. BARRIOS-LANDEROS: "Protective Groups in Organic Synthesis", 2007, WILEY-INTERSICENCE
L. JIANGS. L. BUCHWALD: "Metal-Catalyzed Cross-Coupling Reactions", 2004, WILEY-VCH
J. F. HARTWIG: "Handbook of Organopalladium Chemistry for Organic Synthesis", 2002, WILEY
J. F. HARTWIG: "Modern Amination Methods", 2000, WILEY-VCH
IYAKUHINKAIHATSU: "Development of Pharmaceuticals", vol. 7, 1990, HIROKAWA SHOTEN, article "Design of Molecules", pages: 163 - 198
CHEM. REV., vol. 114, 2014, pages 9154 - 9218
PHARMA. RES., vol. 32, 2015, pages 3526 - 3540
BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
THE AAPS JOURNAL, vol. 17, 2015, pages 339 - 351
GOLDSTEIN, D. M. ET AL.: "High-throughput kinase profiling as a platform for drug discovery", NAT. REV. DRUG DISCOVERY, vol. 7, 2008, pages 391 - 397, XP002544968, DOI: 10.1038/nrd2541
See also references of EP 4006037A4
Attorney, Agent or Firm:
OHTANI PATENT OFFICE (JP)
Download PDF: